THE EFFECTS OF ZOLEDRONIC ACID ON BONE ARCHITECTURE IN PREMENOPAUSAL WOMEN WITH BREAST CANCER RECEIVING ADJUVANT COMBINED OVARIAN SUPPRESSION AND AROMATASE INHIBITOR THERAPY: A RANDOMISED CONTROLLED TRIAL
Grant number: 1114804 | Funding period: 2016 - 2019
In premenopausal women, a new treatment method that reduces oestrogen levels to almost zero significantly reduces the risk of breast cancer recurrence. However, this is likely to cause substantial bone loss leading to fractures. Using a new imaging technique (HR-pQCT), the effects of profound oestrogen deprivation on bone structure in premenopausal women will be studied. The ability of zoledronic acid, a drug that reduces bone loss, to prevent these adverse bone effects will also be examined.